Cybin reports positive phase 2 data for cyb003, demonstrating breakthrough 12-month efficacy in treating major depressive disorder

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced unprecedented 12-month efficacy data from its phase 2 study of cyb003, a proprietary deuterated psilocin program in development for the potential adjunctive treatment of major depressive disorder (“mdd”). as previ.
CYBN Ratings Summary
CYBN Quant Ranking